Pharmerging Market Trends, 2016-2024

Pharmerging Market (Product Type - Pharmaceuticals (Branded Prescription Drugs, Generic Drugs (Branded Generics, Unbranded Generics, and OTC Drugs) and Healthcare (Medical Devices, Diagnostic Instruments, and IT and Record Management); Economic Growth Levels - Tier - 1, Tier - 2, and Tier - 3; Indications - Lifestyle Diseases, Cancer and Autoimmune Diseases, and Infectious Diseases; Distribution Channel - Hospitals, Clinics, Retail Pharmacies, E-commerce, and Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global Pharmerging Market: Snapshot

The global pharmerging market is experiencing a significant rise, especially in the emerging economies across the world. The rising prevalence of non-communicable diseases, aging population, increasing life expectancy, escalating income, surging government expenditure on health care, free trade agreement, and the constant research and development are some of the key factors behind the growth of this market.

With the increasing incidence rate of various diseases, the demand for highly innovative and better outcome products is also increasing, which is likely to result in a substantial growth of this market in the future. The continual innovation and advancements in the drugs for the treatment of a host of diseases are also anticipated to drive this market over the next few years. The global market for pharmerging, which stood at US$552.8 mn in 2015, is expected to rise at a CAGR of 11.30% between 2016 and 2024 and reach a value of US$1.40 bn by the end of 2024.

pharmerging market

Pharmaceutical Products to Witness Strong Growth in Near Future

On the basis of type of product, pharmaceuticals and healthcare are the two main segments of the global market for pharmerging. The pharmaceuticals segment dominated the overall market in 2016 with a share of 65.2%. The scenario is expected to continue like this over the next few years, thanks to the significant rise in the demand for both, the branded as well as generic drugs.

Apart from this, the increasing number of innovative therapies for the treatment of various diseases at affordable price is also projected to boost this segment in the years to come. On the other hand, the healthcare segment is likely to be driven by the growing emphasis on medical devices used in the diagnosis and treatment of a number of diseases.

Based on the indication, the worldwide market for pharmerging has been classified into lifestyle diseases, cancers and autoimmune diseases, and infectious diseases. Among these, lifestyle-borne and cancer and autoimmune diseases are projected to offer lucrative opportunities for the growth of this market with attractiveness index over the forthcoming years.

Asia Pacific to Remain on Top

In terms of the geography, the global pharmerging market reports its presence across Latin America, the Middle East and Africa, Asia Pacific, North America, and Europe. With a share of 53%, Asia Pacific led this market in 2016. Researchers expect this regional market to remain on the top, thanks to rapid urbanization, increasing patent expiration, and the surge in the investments for medical research. China has emerged as the key domestic market for pharmerging in Asia Pacific.

Among other regional markets for pharmerging, Europe and Latin America are likely to witness healthy growth in the near future. Technological advancements, extensive research and development practices, and the increasing awareness regarding the treatment and the management of healthcare facilities are likely to propel the Latin America market. The Europe market is predicted to be drive by the large population size, growing disease prevalence, and the increasing health expenditure in the region.

Huadong Medicine Co. Ltd., Sun Pharmaceutical Industries Ltd., Tata Consultancy Services Ltd., LUPIN, GlaxoSmithKline Plc., AstraZeneca, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Novartis AG, Merck & Co. Inc. F. Hoffmann-La Roche Ltd., Koninklijke Philips N.V., and Abbott Laboratories are the leading players in the global pharmerging market.

Increasing Investments on Research and Development will Augment Growth of Pharmerging Market

With the expanding rate pace of different illnesses, the interest for profoundly creative and better result items is additionally expanding, which is probably going to bring about a considerable development of this market later on. The nonstop development and headways in the medications for the treatment of a large group of infections are likewise expected to drive this market over the course of the following not many years.

The worldwide pharmerging market is encountering a critical ascent, particularly in the arising economies across the world. The rising pervasiveness of non-transmittable sicknesses, maturing populace, expanding future, raising pay, flooding government consumption on medical care, international alliance, and the consistent innovative work are a portion of the critical elements behind the development of this market.

The worldwide pharmerging market is encountering an undeniable degree of rivalry among the main players. The presence of a huge pool of members has kept the seller scene divided while the consistent passage of new players is adding to the flooding level of rivalry inside this market fundamentally. Throughout the next few years, they are probably going to move their concentration towards undiscovered business sectors with possible freedoms. They are additionally expected to include more into vital coordinated efforts that will energize the market advancement amazingly soon.

Geographically, the market is dominated by Asia Pacific on account of the rapid pace of urbanization and rising number of patient pool. This, coupled with the increasing number o patients diagnosed with autoimmune, and lifestyle diseases, along with cancer will also add impetus to the overall growth of this market in the coming years. Among the various nations contributing to the growth of the regional market, China emerged dominant. Besides this, Latin America and Europe markets have also generated significant revenues on account of the extensive research and development facilities and increasing awareness about healthcare facilities present in the respective regions.

The global pharmerging Market has been segmented as follows:

By Product Type

  • Pharmaceuticals
    • Branded Prescription Drugs
    • Generic Drugs
      • Branded Generics
      • Unbranded Generics
    • OTC Drugs
  • Healthcare
    • Medical Devices
    • Diagnostic Instruments
    • Others (IT and record management)

By Indications

  • Lifestyle Diseases
  • Cancer and autoimmune diseases
  • Infectious Diseases
  • Others

By Distribution Channel

  • Hospitals
  • Clinics
  • Retail Pharmacies
  • E-commerce
  • Drug Stores

By Region

  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

What is the total market worth of pharmerging market?

The global pharmerging market was worth US$552.8 mn and is projected to reach a value of US$1.40 bn by the end of 2024

What is the anticipated CAGR of the pharmerging market in the forecast period?

Pharmerging market is anticipated to grow at a CAGR of 11.30% during the forecast period

Which region is expected to project the highest market share in the global pharmerging market?

Europe and latin america accounted for a major share of the global pharmerging market

What are the key driving factors for the growth of the pharmerging market?

Pharmerging market is driven by rising prevalence of non-communicable diseases, aging population, increasing life expectancy, escalating income and surging government expenditure on health care

Who are the key players in the global pharmerging market?

Key players in the global pharmerging market include Huadong Medicine Co. Ltd., Sun Pharmaceutical Industries Ltd., Tata Consultancy Services Ltd., LUPIN, GlaxoSmithKline Plc., AstraZeneca, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Novartis AG, Merck & Co. Inc. F. Hoffmann-La Roche Ltd., Koninklijke Philips N.V., and Abbott Laboratories

    Section 01 Preface 
    1.1. Report Scope and Market Segmentation 
    1.2. Research Highlights

    Section 02 Assumptions and Research Methodology 
    2.1. Assumptions and Acronyms Used
    2.3. Research Methodology

    Section 03 Executive Summary
    3.1. Global Pharmerging Market Snapshot

    Section 04 Market Overview
    4.1. Product Overview
    4.2. Key Industry Developments

    Section 05 Market Dynamics
    5.1. Opportunity Analysis
    5.2. Drivers and Restraints Snapshot Analysis
    5.3. Drivers
           5.3.1. Continuous Research and Development
           5.3.2. Increasing Government Expenditure on Healthcare
           5.3.3. Rising non-communicable diseases (NCDs)
           5.3.4. Free trade agreement
           5.3.5. Growing income
           5.3.6. Aging population and increasing life expectancy
    5.4. Restraints
           5.4.1. Economic challenges in Africa
           5.4.2. Weak or ambiguous patent laws
           5.4.3. Growing medical tourism
           5.4.4. Partnerships and acquisition of local players by MNCs
    5.5. Porter’s Analysis
    5.6. Value Chain Analysis (Medical Devices)
    5.7. Value Chain Analysis (Pharmaceuticals)
    5.8. Mergers and Acquisitions Landscape
    5.9. Reimbursement Scenario
    5.10. Pharmerging Market Outlook

    Section 06 Global Pharmerging Market Analysis, by Product Type
    6.1. Key Findings
    6.2. Introduction
    6.3. Market Forecast by Product Type
           6.3.1. Pharmaceuticals
                    6.3.1.1. Branded Prescription Drugs
                    6.3.1.2. Generic Drugs
                               6.3.1.2.1. Branded Generic
                               6.3.1.2.2. Unbranded Generic
                    6.3.1.3. OTC Drugs
           6.3.2. Healthcare
                    6.3.2.1. Medical Devices
                    6.3.2.2. In Vitro Diagnostic
                    6.3.2.3. Others (IT and record management)
    6.4. Global Pharmerging Market Attractiveness Analysis, by Product Type
    6.3. Key Trends

    Section 07 Global Pharmerging Market Analysis, by Indications
    7.1. Key Findings
    7.2. Introduction
    7.3. Market Forecast by Indications
           7.3.1. Lifestyle Diseases
           7.3.2. Cancers & Autoimmune diseases
           7.3.3. Infectious diseases
           7.3.4. Others
    7.4. Global Pharmerging Market Attractiveness Analysis, by Indications

    Section 08 Global Pharmerging Market Analysis, by Distribution Channel
    8.1. Key Findings
    8.2. Introduction
    8.3. Market Forecast by Distribution Channel
           8.3.1. Hospitals
           8.3.2. Clinics
           8.3.3. Retail Pharmacies
           8.3.4. E-commerce
           8.3.5. Drug Stores
    8.4. Global Pharmerging Market Attractiveness Analysis, by Distribution Channel
    8.5. Key Trends

    Section 09 Global Pharmerging Market Analysis, by Economic Growth Levels
    9.1. Key Findings
    9.2. Introduction
    9.3. Market Forecast by Economic Growth Levels
           9.3.1. Tier-1
           9.3.2. Tier-2
           9.3.3. Tier-3
    9.4. Global Pharmerging Market Attractiveness Analysis, by Economic Growth Levels

    Section 10 Global Pharmerging Market Analysis, by Region 
    10.1. Global Market Scenario, by Country
    10.2. Global Pharmerging Market Value Share Analysis and Market Attractiveness Analysis, by Region
           10.2.1. Market Forecast by Region
           10.2.2. Latin America
           10.2.3. Asia Pacific
           10.2.4. Europe
           10.2.5. Middle East & Africa

    Section 11 Latin America Pharmerging Market Analysis
    11.1. Key Findings
    11.2. Market Overview
    11.3. Latin America Pharmerging Market Value Share Analysis, by Country
    11.4. Latin America Pharmerging Market Forecast, by Country
    11.5. Latin America Pharmerging Market Value Share Analysis, by Product Type
    11.6. Latin America Pharmerging Market Forecast, by Product Type
    11.7. Latin America Pharmerging Market Value Share Analysis, by Indications
    11.8. Latin America Pharmerging Market Forecast, by Indications
    11.9. Latin America Pharmerging Market Value Share Analysis, by Distribution Channel
    11.10. Latin America Pharmerging Market Forecast, by Distribution Channel
    11.11. Latin America Pharmerging Market Attractiveness Analysis

    Section 12 Asia Pacific Pharmerging Market Analysis
    12.1. Key Findings
    12.2. Market Overview
    12.3. Asia Pacific Pharmerging Market Value Share Analysis, by Country
    12.4. Asia Pacific Pharmerging Market Forecast, by Country
    12.5. Asia Pacific Pharmerging Market Value Share Analysis, by Product Type
    12.6. Asia Pacific Pharmerging Market Forecast, by Product Type
    12.7. Asia Pacific Pharmerging Market Value Share Analysis, by Indications
    12.8. Asia Pacific Pharmerging Market Forecast, by Indications
    12.9. Asia Pacific Pharmerging Market Value Share Analysis, by Distribution Channel
    12.10. Asia Pacific Pharmerging Market Forecast, by Distribution Channel
    12.11. Asia Pacific Pharmerging Market Attractiveness Analysis

    Section 13 Europe Pharmerging Market Analysis
    13.1. Key Findings
    13.2. Market Overview
    13.3. Europe Pharmerging Market Value Share Analysis, by Country
    13.4. Europe Pharmerging Market Forecast, by Country
    13.5. Europe Pharmerging Market Value Share Analysis, by Product Type
    13.6. Europe Pharmerging Market Forecast, by Product Type
    13.7. Europe Pharmerging Market Value Share Analysis, by Indications
    13.8. Europe Pharmerging Market Forecast, by Indications
    13.9. Europe Pharmerging Market Value Share Analysis, by Distribution Channel
    13.10. Europe Pharmerging Market Forecast, by Distribution Channel
    13.11. Europe Pharmerging Market Attractiveness Analysis

    Section 14 Middle East & Africa Pharmerging Market Analysis
    14.1. Key Findings
    14.2. Market Overview
    14.3. Middle East & Africa Pharmerging Market Value Share Analysis, by Country
    14.4. Middle East & Africa Pharmerging Market Forecast, by Country
    14.5. Middle East & Africa Pharmerging Market Value Share Analysis, by Product Type
    14.6. Middle East & Africa Pharmerging Market Forecast, by Product Type
    14.7. Middle East & Africa Pharmerging Market Value Share Analysis, by Indications
    14.8. Middle East & Africa Pharmerging Market Forecast, by Indications
    14.9. Middle East & Africa Pharmerging Market Value Share Analysis, by Distribution Channel
    14.10.    Middle East & Africa Pharmerging Market Forecast, by Distribution Channel
    14.11.    Middle East & Africa Pharmerging Market Attractiveness Analysis

    Section 15 Competition Landscape
    15.1. Competition Matrix
    15.2. Pharmerging Market Share Analysis by Company, 2016
    15.3. Company Profiles
           15.3.1 Abbott Laboratories
                    15.3.1.1 Financial Overview
                    15.3.1.2. Product Portfolio
                    15.3.1.3. Business Strategies
                    15.3.1.4. Recent Developments
           15.3.2 Koninklijke Philips N.V.
                    15.3.2.1 Financial Overview
                    15.3.2.2. Product Portfolio
                    15.3.2.3. Business Strategies
                    15.3.2.4. Recent Developments
           15.3.3 F. Hoffmann-La Roche Ltd.
                    15.3.3.1 Financial Overview
                    15.3.3.2. Product Portfolio
                    15.3.3.3. Business Strategies
                    15.3.3.4. Recent Developments
           15.3.4. Merck & Co., Inc.
                    15.3.4.1 Financial Overview
                    15.3.4.2. Product Portfolio
                    15.3.4.3. Business Strategies
                    15.3.4.4. Recent Developments
           15.3.5 Novartis AG
                    15.3.5.1 Financial Overview
                    15.3.5.2. Product Portfolio
                    15.3.5.3. Business Strategies
                    15.3.5.4. Recent Developments
           15.3.6 Johnson & Johnson
                    15.3.6.1 Financial Overview
                    15.3.6.2. Product Portfolio
                    15.3.6.3. Business Strategies
                    15.3.6.4. Recent Developments
           15.3.7 Teva Pharmaceutical Industries Ltd.
                    15.3.7.1 Financial Overview
                    15.3.7.2. Product Portfolio
                    15.3.7.3. Business Strategies
                    15.3.7.4. Recent Developments
           15.3.8. AstraZeneca
                    15.3.8.1 Financial Overview
                    15.3.8.2. Product Portfolio
                    15.3.8.3. Business Strategies
                    15.3.8.4. Recent Developments
           15.3.9. GlaxoSmithKline plc.
                    15.3.9.1 Financial Overview
                    15.3.9.2. Product Portfolio
                    15.3.9.3. Business Strategies
                    15.3.9.4. Recent Developments
           15.3.10. LUPIN
                    15.3.10.1 Financial Overview
                    15.3.10.2. Product Portfolio
                    15.3.10.3. Business Strategies
                    15.3.10.4. Recent Developments
           15.3.11. Tata Consultancy Services Limited
                    15.3.11.1 Financial Overview
                    15.3.11.2. Product Portfolio
                    15.3.11.3. Business Strategies
                    15.3.11.4. Recent Developments
           15.3.12. Sun Pharmaceutical Industries Ltd
                    15.3.12.1 Financial Overview
                    15.3.12.2. Product Portfolio
                    15.3.12.3. Business Strategies
                    15.3.12.4. Recent Developments
           15.3.13. Huadong Medicine Co., Ltd
                    15.3.13.1 Financial Overview
                    15.3.13.2. Product Portfolio
                    15.3.13.3. Business Strategies
                    15.3.13.4. Recent Developments

    List of Tables 

    Table 01: Global Pharmerging Market Size (US$ Bn) Forecast, by Product Type, 2015–2025
    Table 02: Global Pharmerging Market Size (US$ Bn) Forecast, by Pharmaceuticals, 2015–2025
    Table 03: Global Pharmerging Market Size (US$ Bn) Forecast, by Generic Drugs, 2015–2025
    Table 04: Global Pharmerging Market Size (US$ Bn) Forecast, by Health Care, 2015–2025
    Table 05: Global Pharmerging Market Size (US$ Bn) Forecast, by Indications, 2015–2025
    Table 06: Global Pharmerging Market Size (US$ Bn) Forecast, by Distribution Channel, 2015–2025
    Table 07: Global Pharmerging Market Size (US$ Bn) Forecast, by Economic Growth Levels, 2017–2025 
    Table 08: Global Pharmerging Market Size (US$ Bn) Forecast, by Region, 2015–2025
    Table 09: Latin America Pharmerging Market Size (US$ Bn) Forecast, by Country, 2015–2025
    Table 10: Latin America Pharmerging Market Size (US$ Bn) Forecast, by Product Type, 2015–2025
    Table 11: Latin America Pharmerging Market Size (US$ Bn) Forecast, by Pharmaceuticals, 2015–2025
    Table 12: Latin America Pharmerging Market Size (US$ Bn) Forecast, by Generic Drugs, 2015–2025
    Table 13: Latin America Pharmerging Market Size (US$ Bn) Forecast, by Health Care, 2015–2025
    Table 14: Latin America Pharmerging Market Size (US$ Bn) Forecast, by Indications, 2015–2025
    Table 15: Latin America Pharmerging Market Size (US$ Bn) Forecast, by Distribution Channel, 2015–2025
    Table 16: Asia Pacific Pharmerging Market Size (US$ Bn) Forecast, by Country, 2015–2025 
    Table 17: Asia Pacific Pharmerging Market Size (US$ Bn) Forecast, by Product Type, 2015-2025
    Table 18: Asia Pacific Pharmerging Market Size (US$ Bn) Forecast, by Product Type - Pharmaceuticals, 2015-2025
    Table 19: Asia Pacific Pharmerging Market Size (US$ Bn) Forecast, by Product Type – Pharmaceutical Generic Drugs, 2015-2025
    Table 20: Asia Pacific Pharmerging Market Size (US$ Bn) Forecast, by Product Type - Healthcare, 2015-2025
    Table 21: Asia Pacific Pharmerging Market Size (US$ Bn) Forecast, by Indications, 2015-    2025
    Table 22: Asia Pacific Pharmerging Market Size (US$ Bn) Forecast, by Distribution Channels, 2015-2025
    Table 23: Europe Pharmerging Market Size (US$ Bn) Forecast, by Country, 2015–2025
    Table 24: Europe Pharmerging Market Size (US$ Bn) Forecast, by Product Type, 2015–    2025
    Table 25: Europe Pharmerging Market Size (US$ Bn) Forecast, by Pharmaceuticals, 2015–2025
    Table 26: Europe Pharmerging Market Size (US$ Bn) Forecast, by Generic Drugs, 2015–    2025
    Table 27: Europe Pharmerging Market Size (US$ Bn) Forecast, by Health Care Product, 2015–2025
    Table 28: Europe Pharmerging Market Size (US$ Bn) Forecast, by Indications, 2015–2025
    Table 29: Europe Pharmerging Market Size (US$ Bn) Forecast, by Distribution Channel, 2015–2025
    Table 30: Middle East & Africa Pharmerging Market Size (US$ Bn) Forecast, by Country, 2015–2025
    Table 31: Middle East & Africa Pharmerging Market Size (US$ Bn) Forecast, by Product Type, 2015–2025
    Table 32: Middle East & Africa Pharmerging Market Size (US$ Bn) Forecast, by Pharmaceuticals, 2015–2025
    Table 33: Middle East & Africa Pharmerging Market Size (US$ Bn) Forecast, by Generic Drugs, 2015–2025
    Table 34: Middle East & Africa Pharmerging Market Size (US$ Bn) Forecast, by Health Care Product, 2015–2025
    Table 35: Middle East & Africa Pharmerging Market Size (US$ Bn) Forecast, by Indications, 2015–2025
    Table 36: Middle East & Africa Pharmerging Market Size (US$ Bn) Forecast, by Distribution Channel, 2015–2025

    List of Figures

    Figure 01: Market Value Share, by Product type (pharmaceuticals) (2016) Revenue (US$ Bn)
    Figure 02: Market Value Share, by Product type (health care) (2016) Revenue (US$ Bn)
    Figure 03: Market Value Share (US$ Bn), by Indications, (2016)
    Figure 04: Market Value Share (US$ Bn), by Distribution Channel, (2016)
    Figure 05: Global Pharmerging Market Value Share Analysis, by Product Type, 2016 and 2025
    Figure 06: Global Pharmerging Market Revenue (US$ Bn) and Y-o-Y Growth (%) - Pharmaceuticals, 2015–2025
    Figure 07: Global Pharmerging Market Revenue (US$ Bn) and Y-o-Y Growth (%) - Health Care, 2015–2025
    Figure 08: Global Branded Prescription Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
    Figure 09: Global Generic Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
    Figure 10: Global OTC Drugs Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
    Figure 11: Global Medical Devices Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
    Figure 12: Global In Vitro Diagnostics Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–    2025
    Figure 13: Global Pharmerging Market Revenue (US$ Bn) and Y-o-Y Growth (%) - Others (IT and Record Management), 2015–2025
    Figure 14: Global Pharmerging Market Attractiveness Analysis, by Product Type, 2015–2025
    Figure 15: highlights market share, CAGR, and absolute growth index of the global pharmerging market by product type
    Figure 16: Global Pharmerging- Lifestyle Diseases Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
    Figure 17: Global Pharmerging - Cancers and Autoimmune Diseases Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
    Figure 18: Global Pharmerging - Infectious Diseases Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
    Figure 19: Global Pharmerging Other Diseases Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
    Figure 20: Pharmerging Market Attractiveness Analysis, by Indications, 2015–2025
    Figure 21: Global Pharmerging Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 22: Global Pharmerging - Hospitals Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
    Figure 23: Global Pharmerging - Clinics Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–    2025
    Figure 24: Global Pharmerging - Retail Pharmacies Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
    Figure 25: Global Pharmerging - E-commerce Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
    Figure 26: Global Pharmerging - Drug Stores Market Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2025
    Figure 27: Poultry Pharmaceuticals Market Attractiveness Analysis, by Distribution Channel, 2015–2025
    Figure 28: Global Pharmerging Market Value Share Analysis, by Economic Growth Levels, 2017 and 2025
    Figure 29: Global Pharmerging- Tier-1 Market Revenue (US$ Bn), 2015–2025
    Figure 30: Global Pharmerging - Tier-2 Market Revenue (US$ Bn), 2015–2025
    Figure 31: Global Pharmerging - Tier-3 Market Revenue (US$ Bn), 2015–2025
    Figure 32: Pharmerging Market Attractiveness Analysis, by Economic Growth Levels, 2015-2025
    Figure 33: Global Pharmerging Market Value Share Analysis, by Region, 2016 and 2025
    Figure 34: Global Animal Blood Plasma Products and Derivatives Market Attractiveness Analysis, by Region, 2015–2025
    Figure 35: Latin America Pharmerging Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2015–2025
    Figure 36: Latin America Pharmerging Market Attractiveness Analysis, by Country, 2017–2025
    Figure 37: Latin America Pharmerging Market Value Share Analysis, by Country, 2016 and 2025
    Figure 38: Latin America Pharmerging Market Value Share Analysis, by Product Type, 2016 and 2025
    Figure 39: Latin America Pharmerging Market Value Share Analysis, by Indications, 2016 and 2025
    Figure 40: Latin America Pharmerging Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 41: Latin America Pharmerging Market Attractiveness Analysis, by Product Type, 2017–    2025
    Figure 42: Latin America Pharmerging Market Attractiveness Analysis, by Indications, 2017–2025
    Figure 43: Latin America Pharmerging Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 44: Asia Pacific Pharmerging Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2015-    2025
    Figure 45: Asia Pacific Pharmerging Market Attractiveness Analysis, by Country, 2017-2025
    Figure 46: Asia Pacific Pharmerging Market Value Share Analysis, by Country, 2016 and 2025
    Figure 47: Asia Pacific Pharmerging Market Value Share Analysis, by Product Type, 2016 and 2025
    Figure 48: Asia Pacific Pharmerging Market Value Share Analysis, by Product Type – Pharmaceuticals, 2016 and 2025
    Figure 49: Asia Pacific Pharmerging Market Value Share Analysis, by Product Type - Healthcare, 2016 and 2025
    Figure 50: Asia Pacific Pharmerging Market Value Share Analysis, by Indications, 2016 and 2025
    Figure 51: Asia Pacific Pharmerging Market Value Share Analysis, by Distribution Channels, 2016 and 2025
    Figure 52: Asia Pacific Pharmerging Market Attractiveness Analysis, by Product Type, 2017–2025 
    Figure 53: Asia Pacific Pharmerging Market Attractiveness Analysis, by Indications, 2017–2025 
    Figure 54: Asia Pacific Pharmerging Market Attractiveness Analysis, by Distribution Channels, 2017–2025 
    Figure 55: Europe Pharmerging Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2015–2025
    Figure 56: Europe Pharmerging Market Attractiveness Analysis, by Country, 2017–2025
    Figure 57: Europe Pharmerging Market Value Share Analysis, by Country, 2016 and 2025
    Figure 58: Europe Pharmerging Market Value Share Analysis, by Product Type, 2016 and 2025
    Figure 59: Europe Pharmerging Market Value Share Analysis, by Indications, 2016 and 2025
    Figure 60: Europe Pharmerging Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 61: Europe Pharmerging Market Attractiveness Analysis, by Product Type, 2017–2025
    Figure 62: Europe Pharmerging Market Attractiveness Analysis, by Indications, 2017–2025
    Figure 63: Europe Pharmerging Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 64: Middle East & Africa Pharmerging Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 20152025
    Figure 65: Middle East & Africa Pharmerging Market Attractiveness Analysis, by Country, 2017–2025
    Figure 66: Middle East & Africa Pharmerging Market Value Share Analysis, by Country, 2016 and 2025
    Figure 67: Middle East & Africa Pharmerging Market Value Share Analysis, by Product Type, 2016 and 2025
    Figure 68: Middle East & Africa Pharmerging Market Value Share Analysis, by Indications, 2016 and 2025
    Figure 69: Middle East & Africa Pharmerging Market Value Share Analysis, by Distribution Channel, 2016 and 2025
    Figure 70: Middle East & Africa Pharmerging Market Attractiveness Analysis, by Product Type, 2017–2025
    Figure 71: Middle East & Africa Pharmerging Market Attractiveness Analysis, by Indications, 2017–2025
    Figure 72: Middle East & Africa Pharmerging Market Attractiveness Analysis, by Distribution Channel, 2017–2025
    Figure 73: Global Pharmaceutical Market Share Analysis by Company, 2016 (Estimated)
    Figure 74: Global Medical Device Market Share Analysis by Company 2016 (Estimated)

     

Copyright © Transparency Market Research, Inc. All Rights reserved

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic.

By clicking "Accept All", you consent to our use of cookies. Privacy Policy